Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic Dermatitis

• Päätekijät: April W. Armstrong (Tekijä), Andrew F. Alexis (Tekijä), Andrew Blauvelt (Tekijä), Jonathan I. Silverberg (Tekijä), Claire Feeney (Tekijä), Mark Levenberg (Tekijä), Gary Chan (Tekijä), Fan Zhang (Tekijä), Luke Fostvedt (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Adis, Springer Healthcare, 2024-06-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Abstract Introduction Early prediction of abrocitinib efficacy in atopic dermatitis (AD) could help identify candidates for an early dose increase. A predictive model determined week 12 efficacy based on week 4 responses in patients receiving abrocitinib 100 mg/day and assessed the effect of an abro...